TSHA

$4.366.60%0.27

Dopo l'orario di chiusura: 4.360.00 0.00%

Taysha Gene Therapies Inc (TSHA)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$4.09

Aprire:

$4.08

Volume 24 ore:

3,682,282

Volume relativo:

1.49

Capitalizzazione di mercato:

$1.42B

Reddito:

$7.47M

Utile/perdita netta:

-$129.88M

Rapporto P/E:

EPS:

-$0.3962

Flusso di cassa netto:

-$115.33M

1W Prestazione:

+3.07%

1M Prestazione:

-5.83%

6M Prestazione:

-34.34%

1Y Prestazione:

+2.11%

Intervallo 1D:

$4.01$4.38

Intervallo di 1 settimana:

$3.92$4.47

Portata 52W:

$3.46$7.30

Profilo aziendale di Taysha Gene Therapies Inc (TSHA)

Nome

Taysha Gene Therapies Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

(214) 612-0000

Indirizzo

3000 PEGASUS PARK DRIVE, DALLAS, USA

Dipendente

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di TSHA su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Taysha Gene Therapies Inc Azioni (TSHA) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-09-17	Iniziato	Wolfe Research	Outperform
2025-10-21	Iniziato	Raymond James	Strong Buy
2025-07-11	Iniziato	BofA Securities	Buy
2024-06-27	Iniziato	BMO Capital Markets	Outperform
2024-04-09	Iniziato	Piper Sandler	Overweight
2023-02-01	Downgrade	Jefferies	Buy → Hold
2023-01-27	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-11-09	Downgrade	Goldman	Buy → Neutral
2022-03-09	Iniziato	Robert W. Baird	Outperform
2022-03-01	Iniziato	Wells Fargo	Overweight
2022-02-18	Iniziato	SMBC Nikko	Outperform
2021-12-16	Iniziato	Guggenheim	Buy
2021-07-16	Iniziato	Needham	Buy
2021-06-24	Iniziato	Truist	Buy
2021-06-15	Iniziato	BTIG Research	Buy
2021-06-09	Iniziato	Wedbush	Outperform
2021-06-08	Iniziato	JMP Securities	Mkt Outperform
2021-05-19	Iniziato	Cantor Fitzgerald	Overweight
2021-05-11	Resumed	Jefferies	Buy
2021-02-24	Iniziato	William Blair	Outperform
2021-01-05	Iniziato	Oppenheimer	Outperform
2020-10-19	Iniziato	Chardan Capital Markets	Buy
2020-10-19	Iniziato	Goldman	Buy
2020-10-19	Iniziato	Jefferies	Buy
2020-10-19	Iniziato	Morgan Stanley	Overweight

Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	9.77	8.33	15.45	2.50	0.00
Research and development USD (M)	86.40	66.00	56.78	91.17	131.94
Operating expenses USD (M)	120.27	99.79	87.89	164.95	173.27
Operating income USD (M)	-110.50	-91.46	-72.44	-162.45	-173.27
Income before tax USD (M)	-	-	-111.57	-166.01	-174.52
Income tax expense USD (M)	0.00	0.00	0.00	0.00	-
Net income USD (M)	-109.00	-89.30	-111.57	-166.01	-174.52
Basic EPS USD/shares	-0.34	-0.36	-0.96	-3.78	-
Diluted EPS USD/shares	-0.34	-0.36	-0.96	-3.78	-
Basic weighted shares shares (M)	319.71	250.13	116.12	43.95	-
Diluted weighted shares shares (M)	319.71	250.13	116.12	43.95	-

Taysha Gene Therapies Inc Azioni (TSHA) insider trading

Nagendran SukumarJul 10 '26
Officer
Transazione
Proposed Sale
Costo
$6.49
#Azioni
200,000
Valore ($)
1,298,000
#Azioni Totale
0
Nagendran SukumarJul 10 '26
President and Head of R&D
Transazione
Sale
Costo
$6.24
#Azioni
200,000
Valore ($)
1,248,000
#Azioni Totale
936,410
Nagendran SukumarApr 10 '26
Officer
Transazione
Proposed Sale
Costo
$4.63
#Azioni
200,000
Valore ($)
926,000
#Azioni Totale
0
Nagendran SukumarApr 10 '26
President and Head of R&D
Transazione
Sale
Costo
$4.46
#Azioni
200,000
Valore ($)
892,000
#Azioni Totale
1,136,410
Nagendran SukumarApr 10 '26
President and Head of R&D
Transazione
Option Exercise
Costo
$1.71
#Azioni
19,021
Valore ($)
32,526
#Azioni Totale
1,336,410
Rumana Haque-AhmedFeb 27 '26
Officer
Transazione
Proposed Sale
Costo
$4.57
#Azioni
2,405
Valore ($)
10,991
#Azioni Totale
0
Kamran AlamFeb 04 '26
Officer
Transazione
Proposed Sale
Costo
$4.72
#Azioni
1,655
Valore ($)
7,812
#Azioni Totale
0
Rumana Haque-AhmedFeb 04 '26
Officer
Transazione
Proposed Sale
Costo
$4.72
#Azioni
697
Valore ($)
3,290
#Azioni Totale
0
Sean McAuliffeFeb 04 '26
Affiliate - Chief Business Off
Transazione
Proposed Sale
Costo
$4.72
#Azioni
914
Valore ($)
4,314
#Azioni Totale
0
Fred PorterFeb 04 '26
Affiliate-Chief of Staff &
Transazione
Proposed Sale
Costo
$4.72
#Azioni
889
Valore ($)
4,196
#Azioni Totale
0

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Nagendran Sukumar	Officer	Jul 10 '26	Proposed Sale	$6.49	200,000	1,298,000	0
Nagendran Sukumar	President and Head of R&D	Jul 10 '26	Sale	$6.24	200,000	1,248,000	936,410
Nagendran Sukumar	Officer	Apr 10 '26	Proposed Sale	$4.63	200,000	926,000	0
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Sale	$4.46	200,000	892,000	1,136,410
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Option Exercise	$1.71	19,021	32,526	1,336,410
Rumana Haque-Ahmed	Officer	Feb 27 '26	Proposed Sale	$4.57	2,405	10,991	0
Kamran Alam	Officer	Feb 04 '26	Proposed Sale	$4.72	1,655	7,812	0
Rumana Haque-Ahmed	Officer	Feb 04 '26	Proposed Sale	$4.72	697	3,290	0
Sean McAuliffe	Affiliate - Chief Business Off	Feb 04 '26	Proposed Sale	$4.72	914	4,314	0
Fred Porter	Affiliate-Chief of Staff &	Feb 04 '26	Proposed Sale	$4.72	889	4,196	0

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

Oct 02, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 02, 2026

Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more. - Stock Titan

Oct 02, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2026

Sep 11, 2026

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval - Seeking Alpha

Sep 11, 2026

Sep 07, 2026

These 3 Risky Stocks Could Be Sitting on 100% Upside - inkl

Sep 07, 2026

Sep 04, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 04, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 04, 2026

Aug 27, 2026

Taysha Gene Therapies Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - Moomoo

Aug 27, 2026

Aug 23, 2026

Certain Common Stock of Taysha Gene Therapies, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - www.marketscreener.com

Aug 23, 2026

Aug 20, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell? - MarketBeat

Aug 20, 2026

TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - simplywall.st

Aug 20, 2026

Aug 19, 2026

Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest Trading - Analyst Drop Coverage - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - AOL.com

Aug 18, 2026

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail

Aug 18, 2026

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Aug 18, 2026

Aug 14, 2026

RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan

Aug 14, 2026

BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo

Aug 14, 2026

Aug 13, 2026

Taysha Gene Therapies (TSHA) Drops 6.5% as Gene Therapy Stock Approaches Key Support at $5.69 - Bull Flag - Vinanet

Aug 13, 2026

Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - stocktitan.net

Aug 13, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why - MarketBeat

Aug 13, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Aug 13, 2026

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance

Aug 13, 2026

Aug 12, 2026

Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13 - Moomoo

Aug 12, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? - Investing.com

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com India

Aug 12, 2026

Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Canada

Aug 12, 2026

Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 12, 2026

Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView

Aug 12, 2026

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat

Aug 12, 2026

TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 12, 2026